Compare PIM & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIM | ACHV |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | PIM | ACHV |
|---|---|---|
| Price | $3.19 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 73.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.08 | $2.00 |
| 52 Week High | $3.50 | $6.15 |
| Indicator | PIM | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 53.31 |
| Support Level | $3.16 | $4.04 |
| Resistance Level | $3.33 | $5.30 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 84.62 | 56.82 |
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.